HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- cyclohexylimino- 6- methyl- 6,7- dihydro- 5H- benzo(1,3)oxathiol- 4- one

inhibitor of JAK/STAT3 signaling; has antineoplastic activity; structure in first source

Also Known As:

BOT-4-one

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - 2-cyclohexylimino-6-methyl-6,7-dihydro-5H-benzo(1,3)oxathiol-4-one: 4

Experts

1.	Kim, Byung-Hak: 3 articles (11/2017 - 01/2016)
2.	Ye, Sang-Kyu: 3 articles (11/2017 - 01/2016)
3.	Choi, Jung Sook: 3 articles (01/2016 - 05/2011)
4.	Lee, Kwang-Ho: 2 articles (11/2017 - 01/2016)
5.	Lee, Hyun Gyu: 2 articles (01/2016 - 01/2016)
6.	Kang, Tae-Bong: 1 article (11/2017)
7.	Koppula, Sushruta: 1 article (11/2017)
8.	Shim, Do-Wan: 1 article (11/2017)
9.	Shin, Woo-Young: 1 article (11/2017)
10.	Won, Hyung-Sik: 1 article (11/2017)

Related Diseases

1.	Skin Diseases (Skin Disease) 01/01/2016 - "Our study demonstrated that BOT-4-one ameliorates inflammatory skin diseases by suppressing the pathogenic CD4(+) T cell differentiation and overall immune responses." 01/01/2016 - "Topical application of BOT-4-one ameliorated experimentally induced inflammatory skin diseases in mice models such as 2,4,6-trinitrochlorobenzene-induced contact and atopic dermatitis and IL-23-induced psoriasis-like skin inflammation. "
2.	Inflammation (Inflammations) 01/01/2016 - "Immunomodulatory Activities of the Benzoxathiole Derivative BOT-4-One Ameliorate Pathogenic Skin Inflammation in Mice." 01/01/2016 - "Our results suggest that BOT-4-one may have therapeutic potential for the treatment of chronic inflammation associated with autoimmune rheumatoid arthritis." 01/01/2016 - "Topical application of BOT-4-one ameliorated experimentally induced inflammatory skin diseases in mice models such as 2,4,6-trinitrochlorobenzene-induced contact and atopic dermatitis and IL-23-induced psoriasis-like skin inflammation. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2016 - "Topical application of BOT-4-one ameliorated experimentally induced inflammatory skin diseases in mice models such as 2,4,6-trinitrochlorobenzene-induced contact and atopic dermatitis and IL-23-induced psoriasis-like skin inflammation. "
4.	Prostatic Neoplasms (Prostate Cancer) 05/31/2011 - "Consequently, BOT-4-one significantly inhibited STAT3 tyrosine phosphorylation and expression of STAT3 downstream target gene SOCS3 in various human cancer cell lines, and its effect was more potent in JAK3-activated Hodgkin's lymphoma cell line than in JAK2-activated breast cancer and prostate cancer cell lines. "
5.	Peritonitis 11/08/2017 - "Finally, BOT-4-one appeared to be superior to other known NLRP3 alkylators in inhibiting the functionality of the NLRP3 inflammasome and its resulting anti-inflammatory activity was confirmed in vivo using a monosodium urate-induced peritonitis mouse model. "

Related Drugs and Biologics

1.	Inflammasomes
2.	Uric Acid (Urate)
3.	Tyrosine (L-Tyrosine)
4.	Alkylating Agents